Evanko Brian C

Director Evanko Brian C bought 5,000 shares of TNET at $37.70 on 2026-03-04, raising holdings 109.5% to 9,565 shares ($188.5K transaction).

Director Evanko Brian C purchased 5,000 shares at $37.70 on 2026-03-04, expanding his position by 109.5% from 4,565 to 9,565 shares for a total value of $188,500.00. The purchase occurred when TNET was trading -50.6% from its 52-week high of $86.78 and has since risen +10.6% over the past 30 days to a current price of $42.87. Historically, this insider's cross-ticker track record shows 3 prior sells with a 90d well-timed rate of 50.00%, indicating mixed precision in prior transaction timing. The company trades at a P/E of 12.39 with recent quarterly revenue of $1,226,000,000.00 and net income of $89,000,000.00, but full-year revenue growth stands at -0.8%.

Cigna Group exec Brian C Evanko sold 5,368 shares at $300.00 (-9.3% of holdings); stock now $307.14, down 14.4% from 52-week high.

Brian C Evanko sold 5,368 shares of CI at $300.00 on 2025-10-03, reducing his holdings from 57,451 to 52,083 shares. The sale occurred below the current price of $307.14 and well below the 52-week high of $358.58, suggesting the exit was timed before recent momentum rather than at a peak. Evanko's cross-ticker track record shows 2 prior open-market sells with an average 90-day return of +3.2% (poorly timed; stock rose after) and a 90d well-timed rate of 0.00%, indicating a history of selling before rallies rather than declines. At this same ticker (CI), his prior 2 trades also show mixed outcomes: a June 2024 sell followed by a +3.2% 90-day return, consistent with the cross-ticker pattern. The sale represents a modest 9.3% reduction in a large remaining position at a company with strong fundamentals (Revenue $67.2B, Net income $1.6B, Annual growth +26.6%, P/E 15.17).

Evanko sells 4.8K CI shares at $345.01; price now $337.58. One prior CI sale occurred 90d after stock rose +3.1%.

Evanko Brian C sold 4,795 shares of Cigna Group for $1,654,302.81 on 2024-06-24 at $345.01, reducing his stake by -10.5% to 40,934 shares. His only prior trade at Cigna was a sale on 2023-08-02 where the stock subsequently rose +3.1% over 90 days—a poorly timed outcome—with 0 of 1 prior sells well-timed at the 90-day mark. The current price of $337.58 is -7.3% from the 52-week high of $364.08, and the stock is -7.0% over 90 days. Cigna's fundamentals show net income of $-212.0M against $57.3B in revenue, with P/E of 24.88. The transaction reflects a notable reduction in holdings but lacks a distinguishing pattern at this ticker; his cross-ticker sell track record shows 0.00% well-timed rate across all open-market history.